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Biomimetic scaffolds hold great promise for therapeutic repair of cartilage, but although most scaffolds are tested with cells in vitro, there are
very few ex vivo models (EVMs) where adult cartilage and scaffolds are co-cultured to optimize their interaction prior to in vivo studies. This
study describes a simple, non-compressive method that is applicable to mammalian or human cartilage and provides a reasonable
throughput of samples. Rings of full-depth articular cartilage slices were derived from human donors undergoing knee replacement for
osteoarthritis and a 3mm core of a collagen/glycosaminoglycan biomimetic scaffold (Tigenix, UK) inserted to create the EVM. Adult
osteoarthritis chondrocytes were seeded into the scaffold and cultures maintained for up to 30 days. Ex vivo models were stable throughout
experiments, and cells remained viable. Chondrocytes seeded into the EVM attached throughout the scaffold and in contact with the
cartilage explants. Cell migration and deposition of extracellular matrix proteins in the scaffold was enhanced by growth factors
particularly if the scaffold was preloaded with growth factors. This study demonstrates that the EVM represents a suitable model that has
potential for testing a range of therapeutic parameters such as numbers/types of cell, growth factors or therapeutic drugs before progressing to
costly pre-clinical trials. © 2015 The Authors. Cell Biochemistry and Function Published by John Wiley & Sons Ltd.
SIGNIFICANCE
Pre-clinical trials of biomaterials for cartilage repair are very costly, and all too often, studies progress directly from in vitro studies using
isolated cells to in vivo studies without investigating the interaction between the target tissue and the scaffold. Our study uses viable cartilage
from adult human donors with osteoarthritis and therefore represents the exact scenario that the scaffold is designed for. The system is cheap
and simple to set up and is suitable for a 48-well plate format, meaning a reasonable throughput is obtainable. This lends the model to ther-
apeutic drug testing.
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INTRODUCTION
Articular cartilage is a form of hyaline cartilage that
covers the bony articulating ends of synovial joints. This
stiff load-bearing tissue resists tensile forces, compres-
sion and shearing, while maintaining some resilience
and elasticity. The unique biomechanical properties of
articular cartilage are attributed to the complex zonal
arrangement of its constituent macromolecules, collagen
and proteoglycan, which are maintained by cells known
as chondrocytes.1 Injuries to articular cartilage yield poor
intrinsic repair and present a major risk factor in the
development of osteoarthritis (OA) in later life.2 Partial
thickness (chondral) defects that only affect the cartilage
are the most difﬁcult to repair as neighbouring
chondrocytes are incapable of repairing adjacent defects,
and as these injuries do not penetrate the bone, the body
does not initiate a spontaneous repair response.3 The key
factors required for cartilage repair are the recruitment,
retention and proliferation of cells at the defect site,4
and improving cartilage repair has become a major goal
in the tissue engineering ﬁeld.
In the last 20 years, the related ﬁelds of tissue
engineering, regenerative medicine and cell therapy have
emerged as major research areas leading to new develop-
ments in orthopaedic surgery.5,6 These approaches aim to
repair diseased/damaged tissue and promote new tissue
regeneration. One particularly active research area is the
use of biomimetic scaffolds [either used alone or as
vehicles to deliver growth factors (GFs)] to enhance the
repair process.7,8
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While bone regeneration is relatively easy to inﬂuence
with tissue engineering, scaffolds designed to promote the re-
pair of other joint tissues, such as articular and meniscal car-
tilage, and tendon have met with limited success when used
to treat human patients in the clinic.9,10 However, the devel-
opment of scaffolds+/GF remains a key goal in musculo-
skeletal research and is likely to continue to be a growth area
for research and development. Although many in vitro and
in vivo studies are carried out each year searching for the
‘perfect’ scaffold, a huge gulf remains in making the transi-
tion from the production of the scaffold to success in the
clinic. This is partly due to the technical difﬁculties in gener-
ating effectively engineered scaffolds but is also due to a lack
of efﬁcacy of the pre-clinical animal models that are used to
predict human tissue repair responses.11 Often, scaffolds are
simply tested in small laboratory-based projects quantifying
cytotoxicity and cell proliferation prior to progressing to an-
imal trials. The major limitation of these simple studies is that
they fail to address the complexity of the tissue that is being
targeted for repair, i.e. the three-dimensional structure, the
mixture of cell types, the cellular organization of the tissue
and the local autocrine environment.
In this study, we have produced an ex vivo model (EVM)
system that replicates, as far as possible in vitro, the interac-
tion between scaffold and articular cartilage. These EVMs
will allow both the testing of scaffolds as biomaterials and
cell supports but also as delivery devices for GF. In addition
to evaluating the ability of scaffolds and GF to inﬂuence re-
pair, the EVM would also be ideal to test therapeutic drugs.
As such, it has the potential to provide valuable experimental
tools to the medical, veterinary and biological research com-
munities. Following characterization of the EVM, we then
used it to test its suitability to deliver biologically active
GFs [insulin-like growth factor-1 (IGF-1) and transforming
growth factor beta-1 (TGF-β1)] to sites of repair.
To date, the collagen–glycosaminoglycan (CG) scaffold
has been incubated with IGF-1 to load this growth factor
via physical sorption. Previous work has demonstrated that
the IGF-1 released from CG scaffolds had a therapeutic
effect on OA chondrocytes seeded within the CG scaffold
to synthesis cartilaginous extracellular matrix (ECM).9
However, the effects of this system on a host tissue in vivo
is unknown, and therefore, it is desirable to have an EVM
in which to test the interactions of growth factor-loaded
scaffold in close proximity to living cartilage as the interac-
tion between chondrocytes and their microenvironment
plays a key role in cell behaviour.
Towards this goal, this research describes loading a CG
scaffold with bioactive molecules and cells to enhance tissue
regeneration within a novel EVM of articular cartilage repair.
The aims of this study were twofold. Firstly, we aim to
develop a reasonable throughput EVM of cartilage repair
that enables scaffold and cartilage explants to be incubated
in close contact. Secondly, we aim to incorporate bioactive
molecules into the CG scaffold with aim to yield de novo
hyaline articular cartilage repair tissue. In this EVM, the
CG scaffold will be in constant contact with an OA cartilage
explant, which allows a more realistic evaluation of the
potential of this cell-seeded scaffold to induce repair in a
model that includes catabolic enzymes and cytokines
released from chondrocytes from the cartilage explant.
MATERIALS AND METHODS
Materials
Type I acid-insoluble collagen was prepared as described.8
Human recombinant IGF-1 and TGF-β1 were purchased
from R&D Systems. Dulbecco’s modiﬁed eagle medium
was purchased from Invitrogen and Collagenase A from
Roche. Articular cartilage was obtained from patients under-
going total knee replacement surgery with full ethical consent
(NREC 06/Q0108/213) and used to prepare explants, and
primary chondrocytes were derived by collagenase digestion.
Primary antibodies: collagen type I (Rockland), collagen
type II: AVT6E3 (kind gift from Anne Vaughan-Thomas,
University of Cardiff), decorin (R&D Systems), ﬁbronectin
(Santa Cruz). Peroxidase orﬂuorescein isothiocyanate-conjugated
secondary antibodieswere all fromSigma. Collagen types I and II
standards were prepared in-house from bovine skin or human
articular cartilage, respectively. Recombinant human decorin
was from R&D systems. Immobilon Polyvinylidene ﬂuoride
(PVDF) (Millipore) membranes and ECL plus (GE Healthcare)
were used for Western blotting. 1,9-Dimethyl-methylene blue
(DMMB) was purchased from Sigma-Aldrich.
METHODS
Scaffold preparation
Collagen/glycosaminoglycan scaffolds were prepared as
described previously.8
EVM preparation
Full-depth articular cartilage was removed from OA femoral
condyles using a scalpel and 5mm discs created using a bi-
opsy punch (Kai Medical). A 3mm diameter biopsy punch
was then used to punch out a hole in the centre of each disc
to form ring-shaped explants prior to inserting 3mm CG
scaffold discs.
Cell culture
Incubated in media were 3mm CG scaffold discs [Dulbecco’s
modiﬁed eagle medium containing 10% foetal calf serum,
100 IU/100μg/ml penicillin/streptomycin and 20μg/ml
ascorbate-2-phosphate (Sigma) containing IGF-1 (25μg/ml),
TGF-β1 (10μg/ml), IGF-1 plus TGF-β1 or media only for
24h at 37 °C]. Unbound GF was removed, and each scaffold
seeded with 1×105 primary OA chondrocytes as described
previously8 before insertion into each explant ring
(Figure 1A). EVM were cultured in 0.5ml of complete media
or complete media supplemented with exogenous growth
factors for 28days. Media were collected every 3–4days
and replaced with fresh media and fresh exogenous growth
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factors if applicable. Table 1 lists the experimental groups
investigated.
DMMB assay
The total amount of proteoglycan synthesized by the cells
was measured using the DMMB assay.8 Media samples
(40μl) and chondroitin sulphate (CS) standards (40μl) were
added to a 96-well plate, and 250μl of DMMB was added to
each well. The absorbance was measured immediately at
544 nm in a FLUOstar OPTIMA plate reader. The average
amount of accumulated sulphated glycosaminoglycan
(GAG) and standard error of the mean were reported and
data compared using a two-tailed Student’s t-test.
Western blotting
After 28 days, the EVMs were dismantled, the explants
discarded and the amount of extracellular matrix deposited
in the scaffold analysed. Added to each scaffold was
300μl of cell extraction buffer (Invitrogen). The samples
were rotated overnight at 4 °C, centrifuged and the
supernatant mixed with sodium dodecyl sulphate (SDS)
sample buffer before running on SDS electrophoresis and
Western blotting. Standard curves for decorin and type II
collagen were prepared using puriﬁed proteins and used to
convert the relative optical density (OD) values from the
scaffold samples into protein concentrations. All error bars
represent the standard error of the mean, and each experi-
ment was carried out for at least N=3 donors.
Immunohistochemistry
After 28 days, whole EVMs were placed in Tissue-Tek
(Sakara) embedding medium, snap-frozen in liquid
nitrogen and 8μm sections made using a cryostat. Sections
were ﬁxed using a 1:1 solution of acetone and methanol
before probing with primary antibodies and ﬂuorescein
isothiocyanate-conjugated secondary antibodies and
mounting in Vectashield (Vector Laboratories) containing
4′,6-diamidino-2-phenylindole.
RESULTS
EVM histology
A single human OA knee joint can yield enough intact
cartilage to create up to 50 EVMs allowing multiple treatment
Figure 1. Characteristics of human articular cartilage ex vivo model (EVM). (A) EVM construction. (B) EVMs in 48-well plate. (C) EVM after 14 days
in vitro. (D) EVM stained with safranin O. (E) and (F) EVM stained with toluidine blue after 14 days in vitro showing cells added at day 0 populating the
scaffold (E) and in contact with the cartilage (F). Scale bar = 100 μm. OA, osteoarthritis
Table 1. Treatment groups
Scaffold model Growth factor (media) Concentration (ng/ml)
Control 0 0
Adsorbed IGF-1 0 0
IGF IGF-1 100
TGF TGF-β1 10
IGF + TGF IGF-1 + TGF-β1 100, 10
IGF-1, insulin-like growth factor-1; TGF-β1, transforming growth factor
beta-1.
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groups on the same donor tissue. These proved stable enough
in culture to remain intact for many weeks throughout media
changes and other manipulations (Figure 1B and C).
Histological staining demonstrated that the scaffold was in
close contact with the cartilage in the model (Figure 1D) and
that seeded cells populated the scaffold void (Figure 1E) and
grew in close contact with the cartilage after 4weeks in culture
(Figure 1F).
Release of sulphated GAG from the CG scaffold
Ex vivo models pre-treated with adsorbed IGF-1 (AI) and
those treated with IGF-1 plus TGF-β1 released a signiﬁcantly
higher amount of sulphated GAG into the media compared
with the no-GF control group after 28 days (Figure 2), but
there were no signiﬁcant differences between the GF groups.
Decorin deposition within scaffolds
Decorin was detected in all scaffold groups as shown in a
representative Western blot [Figure 3(top)]. However, when
combined with analysis of replicate experiments using OA
chondrocytes derived from other patients (not shown), only
the AI group yielded statistically signiﬁcant (p< 0.05)
higher amounts of decorin deposition in the scaffold when
compared with the control and the other GF groups [Figure 3
(bottom)].
Type I collagen deposition within scaffolds
Type I collagen deposition was detected in all scaffold
groups [Figure 4(top)] and although there was a slight
overall increase in type I collagen with both IGF-1 (I) and
IGF-1 plus TGF-β1 compared with control, neither was
statistically signiﬁcant when combined with data from fur-
ther donors [Figure 4(bottom)]. However, OA chondrocytes
from the AI group deposited statistically signiﬁcantly less
(p<0.01 vs control) type I collagen onto the scaffold compared with the control or any other of the GF conditions
[Figure 4(bottom)]. Scaffolds incubated without cells for
comparable times did not release any detectable type I
collagen when Western blotted (data not shown).
Type II collagen deposition within scaffolds
Low levels of type II collagen were detected in all scaffold
groups [Figure 5(top)], but chondrocytes seeded within the
AI group deposited signiﬁcantly more type II collagen in
the scaffold compared with the control or any other GF
groups when data from all donors were combined
[Figure 5(bottom)]. This result was found to be statistically
signiﬁcant (p< 0.01 vs control).
Immunohistochemistry
A qualitative visualization of the ECM was made by
cryo-sectioning whole EVMs at the ﬁnal time point and
staining for various ECM proteins. In all treatment groups,
cells had deposited a substantial amount of ECM within
the scaffold and between the scaffold and the cartilage
Figure 2. Amount of sulphated GAG released into the media expressed as
fold change compared with the no-growth factors control group. Concentration
of growth factors as in Table 1. N = 3 donors, N= 3 replicates. * represents a
statistically signiﬁcant difference between groups versus control group
(p< 0.05). IGF, insulin-like growth factor; TGF, transforming growth factor
Figure 3. Decorin deposition within the scaffold. (Top) Representative
Western blot demonstrating the amount of decorin deposited by osteoarthri-
tis chondrocytes within each scaffold group. Concentration of growth
factors as in Table 1. Standard = extract of whole human articular cartilage.
(Bottom) Decorin deposition in scaffolds quantiﬁed by densitometry of
Western blot (top) expressed as fold change compared with the no-growth
factor control group. N = 3 donors, N = 3 replicates. * represents a statisti-
cally signiﬁcant difference between groups (p< 0.05) compared with
control. IGF, insulin-like growth factor; TGF, transforming growth factor
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explants (Figure 6). Chondrocytes were observed through-
out the new ECM.
DISCUSSION
An optimal EVM of cartilage repair needs to meet several
criteria:
1. The model needs to maintain the scaffold at a pressure
that will not deform the scaffold but will allow close
contact with the cartilage in a similar fashion to that
which will be experienced in vivo.
2. The model needs to be applicable to multiple species,
scaffold types and tissue types.
3. The model needs to be of reasonable throughput in order
to test a range of compounds or growth factors.
Scaffold design has centred on developing ECM analogues.
For cartilage tissue engineering, highly porous scaffolds with
large surface areas and adequate mechanical strength are
desirable, while a pore size of 100–500μm has been reported
to be optimal for this repair.11,10,12–16 A plethora of different
porous CG scaffolds have been investigated for soft tissue
regeneration (see17,18 for detailed reviews). Collagen is a
key component of many biomedical devices, while the addi-
tion of chondroitin sulphate and a freeze-drying step creates
a porous scaffold that closely resembles the native ECM.
CG scaffolds are promising regeneration templates for differ-
ent tissues including conjunctiva, heart valves, tendon and
ligaments.19–22 The most extensive research has focused on
skin and peripheral nerve regeneration and has yielded
substantial success, as demonstrated by Federal Drugs
Authority (FDA) approval.17 The CG scaffold used in this
EVM is composed of type I collagen and chondroitin sulphate
that was freeze-dried to create a porous microstructure and
chemically cross-linked to enhance its mechanical properties.
CG scaffolds possessed highly interconnected porous archi-
tectures with an average pore size of 216+/ 39μm.8
Growth factor-directed repair has been reported to
produce a better-quality repair tissue.23 Growth factors are
soluble proteins that stimulate cell proliferation and
differentiation and may be used to aid cell migration, and
to increase matrix production.4,13 In vivo cell–ECM interac-
tions provide adequate signals to cells via growth factors to
induce or maintain a desired state of cell differentiation;
thus, these proteins play an important role in in vitro tissue
engineering.24
Insulin-like growth factor-1, an anabolic growth factor
involved in cartilage development and homeostasis,25,26
has been extensively investigated for use in articular carti-
lage repair.25–29 Fortier et al. demonstrated that the addition
Figure 4. Type I collagen deposition within the Scaffold. (Top) Represen-
tative Western blot demonstrating the amount of type I collagen deposited
by osteoarthritis chondrocytes within each scaffold group. Concentration
of growth factors as in Table 1. Standard = type I collagen standard.
(Bottom) Type I collagen deposition in scaffolds quantiﬁed by densitometry
of Western blot (top) expressed as fold change compared with the no-growth
factor control group. N = 3 donors, N = 3 replicates. * represents a statistically
signiﬁcant difference between groups (p< 0.01) compared with control. IGF,
insulin-like growth factor; TGF, transforming growth factor
Figure 5. Type II collagen deposition within the scaffold. (Top) Represen-
tative Western blot demonstrating the amount of type II collagen deposited
by osteoarthritis chondrocytes within each scaffold group. Concentration of
growth factors as in Table 1. Standard = extract of articular cartilage (Bot-
tom) Type II collagen deposition in scaffolds quantiﬁed by densitometry
of Western blot (top) expressed as fold change compared with the no-
growth factor control group. N = 3 donors, N = 3 replicates. * represents a
statistically signiﬁcant difference between groups (p< 0.05) compared with
control. IGF, insulin-like growth factor; TGF, transforming growth factor
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of 10–100ng/ml IGF-1 enhanced the levels of proteoglycan
and type II collagen synthesized by chondrocytes seeded in
ﬁbrin matrices and that the cells maintained their phenotype
in vitro.28 In addition, IGF-1 also protects the ECM from
interleukin-1 and tumour necrosis factor α-mediated degrada-
tion during cartilage injury.30–32 In vivo, IGF-1-loaded ﬁbrin
matrices enhanced the formation of hyaline-like repair tissue
compared with controls in full-thickness articular cartilage
defects in horses.25 In addition, Tuncel et al. reported that
collagen sponges loaded with 5μg IGF-1 enhanced the tissue
response and produced signiﬁcantly better gross, histological
and histochemical neocartilage compared with collagen
sponge controls in a rabbit osteochondral defect model.26
A number of different studies have reported that the
addition of TGF-β1 enhances the production of cartilage
ECM proteins such as proteoglycan and type II collagen
under in vitro conditions.33–35 Yaeger et al. added exoge-
nous IGF-1 and TGF-β1 both singly and in combination to
dedifferentiated human articular chondrocytes and studied
the effect of adding growth factors to serum-free media on
cell proteoglycan and type II collagen synthesis.36 Neither
IGF-1 nor TGF-β1 alone stimulated these cells to produce
aggrecan or type II collagen; however, the combination of
both growth factors induced mRNA expression of these
proteins. The results of their study imply that the addition
of both growth factors yielded a synergistic response that
induced chondrogenesis in this cell type.
The balance between catabolic and anabolic factors is
required to maintain homeostasis of tissue turnover. Anabolic
growth factors include IGF-1, TGF-β and bone morphogenic
proteins (BMPs), whereas tumour necrosis factor (TNF)-α
and interleukin (IL)-1β are catabolic factors. In OA, highly
catabolic factors dominate matrix turnover; therefore, despite
the initial increase in matrix synthesis in early OA, a net loss
of proteoglycans is a key feature of all stages of osteoarthritic
cartilage degeneration.37,38 Cells within a scaffold that is in
contact with a cartilage explant in vitro or implanted into a
cartilage defect in vivo will be affected by a combination of
both catabolic and anabolic signals from those cells in the host
tissue. Thus, creating an EVM using cartilage explants allows
the effect of adding growth factors to seeded cells to be
assessed in a more natural environment.
Pabbruwe et al. investigated an ex vivo cartilage model to
enhance the integration of implanted cartilage with host
tissue.39 Bovine nasal chondrocytes were seeded within a
collagen scaffold implant that was then sandwiched between
two bovine cartilage explants to induce the cells to migrate
between the explants and to integrate with the cartilage
tissue. After 40 days, the cartilage–implant–cartilage
construct appeared macroscopically as a continuous tissue
section and full integration was also observed via histologi-
cal analysis. The implanted chondrocytes migrated into the
mature tissue of each explant and induced ECM remodel-
ling, which resulted in integration. Furthermore, the
cell-seeded implants yielded a higher cartilage repair index
and tensile strength than cell-free control, which indicated
the potential of this model for achieving integration of repair
cartilage in vivo.
An alternative cartilage EVM involved implanting
chondrocytes into a cartilage explant adjacent to a
decellularized cartilage matrix and measuring cell adhesion,
migration and ECM production after 28 days.40 The results
showed that chondrocytes adhered to the cartilage explant
but did not migrate into the acellular cartilage region,
indicating that low chondrocyte migration into host cartilage
occurs in vivo.
The scaffold/explant EVM described in this study
provides a valuable model for studying the interactions
between a biomimetic scaffold and the tissue that it is
designed to be repairing. The model is applicable to most
mammalian articular cartilages with the only restriction
being the area of cartilage available. This study used a
5mm disc as the starting point in order to maximize the
signal generated from ECM production, but we have also
created 3mm discs with 1mm scaffolds successfully. The
system also allows a reasonable throughput as 5mm EVMs
will ﬁt in a 96-well plate format if necessary. Integration of
the scaffold with the explants can be measured by simple
‘push out’41 studies, and the scaffold and explants are easily
separated at the end of the experiment in order to analyse the
relative amounts of ECM deposition or degradation in
the scaffold or the tissue. Similarly, protease activity in the
explants, scaffold and media can also be measured. In
addition, the distribution of cells within the scaffold or
Figure 6. Localization of extracellular matrix proteins in the ex vivo model. (A) Immunostaining for ﬁbronectin. (B) Immunostaining for type I collagen. c:
articular cartilage explant; s: scaffold. Scale bar = 50 μm
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explants can also be analysed by simple histology or
immunohistocytochemistry.
In our study, the DMMB assay demonstrated that cells
seeded within the AI group produced the highest level of
sulphated GAG release into the media (Figure 2). The
DMMB assay was utilized to monitor GAG levels at every
media change, but the assay is primarily a measure of
degradation, e.g. proteoglycan released by proteolysis of
cartilage, rather than synthesis. Hence, Western blots using
decorin as a marker of cartilage proteoglycan were also car-
ried out in order to get a better estimation of proteoglycan
deposition in the scaffold (Figure 3). Both assays demon-
strated that the chondrocytes from the endogenous IGF-1
group yielded a signiﬁcantly higher amount of GAG release
from or decorin deposition into the scaffold when compared
with the control group. We consider that the combination of
these two assays points to an overall increase in proteogly-
can synthesis. Although decorin is a relatively minor
component of the cartilage when compared with aggrecan,
it is much easier to measure accurately, and therefore, we
use it as a surrogate marker of proteoglycan content. It
should be noted that the molecular weight of decorin depos-
ited in the scaffolds is between 200–250KDa and that in the
articular cartilage control is slightly higher [Figure 3(top)].
Decorin undergoes considerable glycosylation both in vitro
and in vivo, and therefore, its molecular weight is consider-
ably higher than that often quoted in the literature (48 kDa),
which represents the unglycosylated core protein.42
Type I collagen was detected in all groups analysed by
Western blotting (Figure 4). Type I collagen is synthesized
by OA chondrocytes and is generally considered to be a
marker of cells that have dedifferentiated into a ﬁbroblastic
or hypertrophic cell phenotype.43,44 There was signiﬁcantly
less type I collagen in the AI group than the control group or
any of the other added GF groups. Although values in the
added GF groups were slightly elevated compared with
those in the control group, none of these were signiﬁcant.
Although a desirable result, it is not clear why the AI group
would down-regulate collagen type I deposition compared
with all other groups, but it is possible that IGF-1 bound
to the scaffold enhances then chondrogenic phenotype more
than when it is free in solution. This hypothesis is borne out
by the data in (Figure 5) where chondrocytes in the AI group
produced signiﬁcantly more type II collagen deposition on
the scaffold than any of the other groups.
There are a number of possible explanations as to why
IGF-1 bound to the scaffold should be more effective than
IGF-1 added to the media. The growth factor may be
protected from proteolytic digestion or from IGF-binding
proteins allowing a more sustained release of IGF-1 over
time compared with adding multiple doses of exogenous
IGF-1. The stimulation of type II collagen and decorin
production implies that the AI scaffolds release a therapeutic
dosage of IGF-1, which aids maintenance of the cell
phenotype and stimulates an anabolic response.
In each case, samples for Western blotting represent the
extraction of the contents of a whole scaffold with no
normalization for total DNA or protein. Previous data in
our laboratory has demonstrated that there are no signiﬁcant
differences in cell number between treatment groups during
the timecouse nor in total protein content of the scaffolds.
The latter is due possibly to the contribution of serum
albumin from the calf serum in the media, which appears
to bind to the scaffold despite washing prior to extraction
(not shown). This protein masks any small changes in the
total protein levels that may have been caused by the growth
factors. Therefore, we believe that any changes that we de-
tect by Western blot represent a change of a speciﬁc ECM
protein relative to the total protein content of the scaffold.
It will now be necessary to analyse the cartilage explants
from the EVM to determine if there are measurable increases
in protein content or whether these will be too small to detect
above normal cartilage metabolism. Preliminary data have also
been acquired (not shown) relating to the catabolic processes in
both the cartilage explant and seeded cells, and this will be the
subject of a later publication.
CONCLUSIONS
This study has demonstrated that the EVM described in this
study is a suitable model for studying anabolic stimuli that
have been applied speciﬁcally to enhance chondrogenesis
and repair in a biomimetic scaffold.
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